Viridian Therapeutics Stock Price, News & Analysis

Viridian Therapeutics, Inc. (Nasdaq: VRDN) is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. According to company disclosures, Viridian applies its expertise in antibody discovery and protein engineering to create differentiated therapeutic candidates directed at previously validated drug targets in commercially established disease areas. The company is based in Waltham, Massachusetts and its common stock trades on The Nasdaq Stock Market LLC under the symbol VRDN.

Viridian’s lead area of focus is thyroid eye disease (TED), a rare autoimmune disorder affecting the tissues around the eyes. The company is advancing multiple anti–insulin-like growth factor-1 receptor (IGF‑1R) candidates in the clinic for TED across both active and chronic forms of the disease. Its pivotal TED program centers on veligrotug (also referred to as VRDN‑001), an intravenously delivered, anti‑IGF‑1R monoclonal antibody in late-stage development. Viridian has conducted two global phase 3 clinical trials, THRIVE and THRIVE‑2, designed to evaluate veligrotug’s efficacy and safety in patients with active and chronic TED, respectively. Company reports state that both trials met their primary and all secondary endpoints and showed a rapid onset of clinical benefit, including statistically significant and clinically meaningful effects on measures such as proptosis and diplopia, with veligrotug generally well tolerated.

Building on the veligrotug program, Viridian is also developing elegrobart (VRDN‑003), a subcutaneously delivered, half‑life extended anti‑IGF‑1R antibody. VRDN‑003 shares the same binding domain as veligrotug and has been engineered for a longer half‑life. It is being studied as a potential subcutaneous therapy for TED in two global phase 3 pivotal trials, REVEAL‑1 and REVEAL‑2, which evaluate dosing every four weeks and every eight weeks in patients with active and chronic TED. Company materials describe VRDN‑003 as designed for administration via a low‑volume autoinjector that patients could self‑administer at home, with dosing regimens intended to align with exposure levels associated with clinical activity observed for veligrotug in earlier studies.

Beyond IGF‑1R inhibition, Viridian is expanding its TED-focused pipeline with an anti–thyroid‑stimulating hormone receptor (TSHR) program. The company describes this program as a half‑life extended monoclonal antibody that inhibits TSHR and is designed for subcutaneous delivery in an autoinjector with extended dosing intervals. The TSHR program is being advanced as a potential therapy for TED or Graves disease, reflecting Viridian’s strategy of addressing multiple biologic drivers implicated in thyroid-related autoimmune conditions.

Viridian is also developing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors with potential application across multiple autoimmune diseases. This portfolio includes VRDN‑006, described as a highly selective Fc fragment that inhibits FcRn and is designed as a convenient subcutaneous, self‑administered option. In a phase 1 healthy volunteer trial, VRDN‑006 demonstrated proof‑of‑concept reductions in immunoglobulin G (IgG) consistent with the FcRn inhibitor class and was reported to spare albumin and low‑density lipoprotein (LDL), with the program described as generally well tolerated. Viridian’s second FcRn candidate, VRDN‑008, is characterized as a bi‑specific, half‑life extended FcRn inhibitor that combines an Fc fragment with an albumin‑binding domain. Preclinical data in non‑human primates disclosed by the company indicate that VRDN‑008 showed a longer half‑life and more sustained IgG reduction than efgartigimod after a single high‑dose head‑to‑head study.

Across these programs, Viridian emphasizes a development strategy that targets serious and rare conditions where validated biological pathways already exist, and where the company believes differentiated antibody engineering can yield therapeutic profiles that may be attractive to patients, physicians, and payers. In TED, Viridian’s clinical and regulatory efforts include late-stage intravenous and subcutaneous candidates, as well as plans for geographic expansion through regulatory submissions such as a Marketing Authorization Application to the European Medicines Agency, as described in company press releases. In addition, Viridian has entered into a collaboration and license agreement with Kissei Pharmaceutical Co., Ltd., granting Kissei an exclusive license to develop and commercialize products containing veligrotug and VRDN‑003 in Japan, with Viridian retaining manufacturing responsibilities for those products under specified circumstances and being eligible for upfront, milestone, and royalty payments.

Viridian’s disclosures also describe steps toward building commercial capabilities around its TED portfolio, including preparations for a potential U.S. launch of veligrotug and subsequent commercialization of VRDN‑003, subject to regulatory approvals. The company has discussed assembling leadership in areas such as sales, market access, patient services, and medical affairs, and focusing on a defined group of physicians who are key prescribers in the TED treatment landscape. Financing transactions, including public equity offerings, royalty financing agreements, and credit facilities, have been highlighted by Viridian as mechanisms to support its clinical programs and anticipated commercialization activities.

Overall, Viridian Therapeutics presents itself as a clinical-stage biopharmaceutical company with a concentrated focus on antibody-based therapies for serious and rare diseases, particularly thyroid eye disease and autoimmune conditions where modulation of IGF‑1R, TSHR, or FcRn pathways may provide clinical benefit. The company’s pipeline spans late-stage pivotal trials in TED and earlier-stage FcRn inhibitor programs, all underpinned by its stated capabilities in antibody discovery and protein engineering.

Business focus and therapeutic areas

According to Viridian’s public statements, the company’s core business focus includes:

• Thyroid eye disease (TED): Development of intravenous and subcutaneous anti‑IGF‑1R antibodies (veligrotug and VRDN‑003/elegrobart) in global phase 3 clinical programs, and advancement of an anti‑TSHR monoclonal antibody program as a potential therapy for TED or Graves disease.
• Autoimmune diseases: Advancement of a portfolio of FcRn inhibitors (VRDN‑006 and VRDN‑008) with potential application in multiple autoimmune conditions, supported by early clinical and preclinical data on IgG reduction and pharmacokinetic properties.
• Antibody engineering: Use of antibody discovery and protein engineering expertise to generate differentiated candidates for validated targets, with an emphasis on half‑life extension, route of administration (intravenous vs. subcutaneous), and dosing schedules designed for patient convenience.

Regulatory and clinical development context

Viridian has reported several notable regulatory and clinical milestones for its TED programs. The company has stated that veligrotug received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for TED, and that the FDA accepted a Biologics License Application (BLA) for veligrotug with Priority Review and a Prescription Drug User Fee Act (PDUFA) target action date. The BLA is supported by data from the THRIVE and THRIVE‑2 phase 3 trials, which, according to Viridian, met all primary and secondary endpoints and demonstrated rapid onset of clinical benefit, including improvements in proptosis and diplopia, with veligrotug generally well tolerated.

For VRDN‑003/elegrobart, Viridian has described two ongoing global phase 3 pivotal clinical trials, REVEAL‑1 and REVEAL‑2, in active and chronic TED, respectively, assessing subcutaneous dosing every four or eight weeks. Company communications note that enrollment targets in these studies were exceeded, driven by what Viridian characterizes as strong patient demand, and that topline data readouts are planned on a defined timeline.

Collaborations and geographic reach

Viridian’s collaboration with Kissei Pharmaceutical Co., Ltd., as disclosed in an 8‑K filing, grants Kissei an exclusive license to develop and commercialize veligrotug and VRDN‑003 in Japan, including for potential treatment of TED. Under this agreement, Kissei is responsible for development and regulatory activities in Japan, while Viridian maintains certain manufacturing responsibilities and is eligible for upfront, milestone, and tiered royalty payments based on net sales in that territory. This collaboration illustrates Viridian’s approach to expanding the reach of its TED therapies beyond the United States through regional partnerships.

Stock listing and corporate governance

Viridian Therapeutics’ common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the ticker symbol VRDN, as noted in multiple Form 8‑K filings. The company has an Amended and Restated 2016 Equity Incentive Plan and has disclosed shareholder approvals of amendments to increase the number of shares available for issuance under that plan, as well as the adoption of an employee stock purchase plan. Viridian also reports periodic inducement grants of stock options to new employees under Nasdaq Listing Rule 5635(c)(4), reflecting the use of equity-based compensation as part of its talent strategy.

FAQs about Viridian Therapeutics, Inc. (VRDN)

• What does Viridian Therapeutics do?
  Viridian Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. Its work centers on antibody discovery and protein engineering to create differentiated therapeutic candidates for validated drug targets, with a primary focus on thyroid eye disease and autoimmune conditions involving IGF‑1R, TSHR, and FcRn pathways.
• What is Viridian’s lead therapeutic area?
  Viridian’s lead therapeutic area is thyroid eye disease (TED). The company is advancing multiple anti‑IGF‑1R antibodies, including veligrotug and VRDN‑003/elegrobart, in global phase 3 clinical programs for patients with active and chronic TED, and is also developing an anti‑TSHR monoclonal antibody program as a potential therapy for TED or Graves disease.
• What is veligrotug?
  Veligrotug (also referred to as VRDN‑001) is an intravenously delivered, anti‑insulin-like growth factor‑1 receptor (IGF‑1R) monoclonal antibody in late-stage development for thyroid eye disease. According to Viridian, veligrotug has been evaluated in two global phase 3 trials, THRIVE and THRIVE‑2, which met all primary and secondary endpoints and showed rapid onset of clinical benefit, including improvements in proptosis and diplopia, with the therapy generally well tolerated.
• What is VRDN‑003 (elegrobart)?
  VRDN‑003, also referred to as elegrobart, is a subcutaneously delivered, half‑life extended anti‑IGF‑1R antibody being developed as a potential therapy for thyroid eye disease. It shares the same binding domain as veligrotug and has been engineered for a longer half‑life. Viridian is conducting two global phase 3 pivotal trials, REVEAL‑1 and REVEAL‑2, to evaluate VRDN‑003 in patients with active and chronic TED using every‑four‑week and every‑eight‑week dosing schedules.
• What are VRDN‑006 and VRDN‑008?
  VRDN‑006 and VRDN‑008 are part of Viridian’s neonatal Fc receptor (FcRn) inhibitor portfolio. VRDN‑006 is described as a highly selective Fc fragment that inhibits FcRn and is designed for convenient subcutaneous self‑administration; in a phase 1 healthy volunteer trial it showed IgG reduction consistent with the FcRn inhibitor class and spared albumin and LDL. VRDN‑008 is a bi‑specific, half‑life extended FcRn inhibitor that combines an Fc fragment with an albumin‑binding domain and has shown a longer half‑life and more sustained IgG reduction than efgartigimod in a non‑human primate study.
• Where is Viridian Therapeutics headquartered?
  Viridian states that it is based in Waltham, Massachusetts. Its SEC filings list a Waltham, Massachusetts location as the address for the company’s principal offices.
• On which exchange does VRDN trade and what is the security class?
  Viridian Therapeutics’ common stock, with a par value of $0.01 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the ticker symbol VRDN, as disclosed in multiple Form 8‑K filings.
• Does Viridian have any major collaboration agreements?
  Yes. Viridian has entered into a Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. Under this agreement, Kissei has an exclusive license to develop and commercialize products containing veligrotug and VRDN‑003 in Japan, including for potential treatment of thyroid eye disease, and a non‑exclusive license to manufacture such products for use in Japan under certain circumstances. Viridian is eligible for an upfront payment, development, regulatory and sales milestones, and tiered royalties on net sales, while retaining certain manufacturing responsibilities.
• How does Viridian describe its approach to drug development?
  Viridian describes its approach as leveraging expertise in antibody discovery and protein engineering to develop differentiated therapeutic candidates against previously validated targets in commercially established disease areas. This includes designing antibodies with properties such as half‑life extension, specific routes of administration, and dosing intervals intended to align with patient and physician needs in serious and rare diseases.
• Is Viridian already a commercial-stage company?
  Company communications characterize Viridian as a biopharmaceutical company focused on discovering, developing, and commercializing medicines, and describe preparations for potential commercial launches of veligrotug and VRDN‑003, subject to regulatory approvals. These materials emphasize late-stage clinical development and commercial readiness activities rather than an established history of product sales.